The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes

被引：18
作者：
Steen, Oren [1 ]
Goldenberg, Ronald M. [2 ]
机构：
[1] LMC Diabet & Endocrinol, 1929 Bayview Ave,Suite 107, Toronto, ON M4G 3E8, Canada
[2] LMC Diabet & Endocrinol, Thornhill, ON, Canada
来源：
CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 05期
关键词：
type; 2; diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; SGLT2; INHIBITORS; BLOOD-PRESSURE; ADD-ON; KIDNEY-DISEASE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; SAFETY; EFFICACY;
D O I：
10.1016/j.jcjd.2017.08.241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 (SGTL2) inhibitors are a novel class of antihyperglycemic agents that work in an insulin-independent manner by promoting urinary glucose excretion. In addition to efficacious glucose lowering, they exert beneficial effects on blood pressure and weight while avoiding hypoglycemia unless combined with insulin or insulin secretagogues. This review explores the mechanism of action of SGLT2 inhibitors, their effects on glycated hemoglobin, weight, blood pressure and hypoglycemia, potential adverse effects, renal considerations and cardiovascular outcomes. (C) 2017 Canadian Diabetes Association.
引用
收藏
页码：517 / 523
页数：7
相关论文
共 73 条
  • [21] Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
    Ferrannini, Ele
    Jimenez Ramos, Silvia
    Salsali, Afshin
    Tang, Weihua
    List, James F.
    [J]. DIABETES CARE, 2010, 33 (10) : 2217 - 2224
  • [22] The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
    Gembardt, Florian
    Bartaun, Christoph
    Jarzebska, Natalia
    Mayoux, Eric
    Todorov, Vladimir T.
    Hohenstein, Bernd
    Hugo, Christian
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 307 (03) : F317 - F325
  • [23] Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
    Goldenberg, Ronald
    Clement, Maureen
    Hanna, Amir
    Harper, William
    Main, Andrea
    Retnakaran, Ravi
    Sherifali, Diana
    Woo, Vincent
    Yale, Jean-Francois
    Cheng, Alice Y. Y.
    [J]. CANADIAN JOURNAL OF DIABETES, 2016, 40 (03) : 193 - 195
  • [24] Health Canada, 2014, SUMM BAS DEC INV
  • [25] Health Canada, 2016, SUMM SAF REV SGLT2 I
  • [26] Health Canada, 2015, SUMM BAS DEC JARD
  • [27] Health Canada, 2014, SUMM BAS DEC FORX
  • [28] Janssen Pharmaceutical Companies, 2013, CAN ADV COMM M
  • [29] Janssen Pharmaceuticals, 2013, 204042 NDA JANSS PHA
  • [30] Janssen Research & Development LLC., 2016, STUD EFF CAN JNJ 284
12345678